Montelukast + Placebo

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Upper Respiratory Infection

Conditions

Upper Respiratory Infection

Trial Timeline

Oct 1, 2003 → Jul 1, 2007

NCT ID

NCT00189475

About Montelukast + Placebo

Montelukast + Placebo is a approved stage product being developed by Merck for Upper Respiratory Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT00189475. Target conditions include Upper Respiratory Infection.

What happened to similar drugs?

5 of 14 similar drugs in Upper Respiratory Infection were approved

Approved (5) Terminated (1) Active (9)

✅Remimazolam TosilateJiangsu Hengrui MedicineApproved

✅BOTOXAbbVieApproved

🔄Muntelukast + PlaceboMerckPhase 3

🔄IFF flavor 316 282, Paracetamol, PseudoephedrineNovartisPhase 3

🔄Paracetamol (500 mg)/dimethindene maleate (1 mg)/ phenylephrine hydrochloride (10 mg) tablets + Paracetamol (500 mg) tabletsNovartisPhase 3

✅diclofenac potassium + nimesulideNovartisApproved

✅Diclofenac gelNovartisApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00599534	Phase 2	Withdrawn	Dec 1, 2007	Dec 1, 2009	Sleep Apnea
NCT00406094	Approved	UNKNOWN	Nov 1, 2006	Dec 1, 2009	Rhinitis
NCT00189462	Approved	Completed	Mar 1, 2004	Dec 1, 2005	Acute Otitis Media
NCT00189475	Approved	Completed	Oct 1, 2003	Jul 1, 2007	Upper Respiratory Infection
NCT00590772	Approved	Completed	May 1, 2003	Jan 1, 2009	Perennial Allergic Rhinitis
NCT01011452	Approved	Completed	May 1, 2001	Oct 1, 2004	Acute Asthma Exacerbation

Competing Products

20 competing products in Upper Respiratory Infection

See all competitors

Product	Company	Stage	Hype Score
Nivolumab 100 MG in 10 ML Injection	Ono Pharmaceutical	Phase 2	31
Remimazolam Tosilate	Jiangsu Hengrui Medicine	Approved	43
ABBV-950 + BOTOX + Placebo for ABBV-950	AbbVie	Phase 1	21
BOTOX + Placebo for BOTOX	AbbVie	Phase 2	35
BOTOX	AbbVie	Approved	43
MK-3475 and BCG	Merck	Phase 2	42
Muntelukast + Placebo	Merck	Phase 3	36
IFF flavor 316 282, Paracetamol, Pseudoephedrine	Novartis	Phase 3	40
Paracetamol (500 mg)/dimethindene maleate (1 mg)/ phenylephrine hydrochloride (10 mg) tablets + Paracetamol (500 mg) tablets	Novartis	Phase 3	40
diclofenac potassium + nimesulide	Novartis	Approved	35
Diclofenac gel	Novartis	Approved	43
IFF flavor 316 282, Paracetamol , Phenylephrine, Guaifenesin	Novartis	Phase 3	40
Domvanalimab + Zimberelimab + Capecitabine + Fluorouracil + Leucovorin + Oxaliplatin + Nivolumab	Gilead Sciences	Phase 3	44
Azithromycin SR	Pfizer	Phase 3	40
Nivolumab	Bristol Myers Squibb	Pre-clinical	26
Nivolumab	Bristol Myers Squibb	Pre-clinical	26
REGN475/SAR164877 + Placebo (for REGN475/SAR164877)	Regeneron Pharmaceuticals	Phase 2	27
IPN10200 + IPN10200 Placebo + Dysport	Ipsen	Phase 1/2	36
AboBoNT-A + OnaBoNT-A	Ipsen	Approved	40
Botulinum toxin type A	Ipsen	Phase 3	37